Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection
暂无分享,去创建一个
S. Sarin | D. Amarapurkar | S. Hamid | M. Lai | M. Omata | E. Gane | W. Jafri | S. Bowden | T. Piratvisuth | J. Jia | J. Sollano | M Omata | W. Hardikar | R Guan | A Chutaputti | N Leung | J Sollano | E Gane | S Bowden | A. Chutaputti | T Piratvisuth | G W McCaughan | D Amarapurkar | W C Chow | G Dore | S S Hamid | W Hardikar | C K Hui | W Jafri | J-D Jia | M-Y Lai | L Wei | S Sarin | R Tateishi | R. Guan | G. Dore | R. Tateishi | G. McCaughan | L. Wei | C. Hui | N. Leung | W. Chow | L. Wei
[1] J. Hoefs,et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[2] P. Marcellin,et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.
[3] R. Fisher,et al. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[4] M. A. al Karawi,et al. Dual infection with hepatitis C and B viruses: clinical and histological study in Saudi patients. , 1997, Hepato-gastroenterology.
[5] G. Farrell. Consensus among consensus conferences on management of hepatitis C: What we knew then and are still sure about, what we are newly sure about, and what we still need to know , 2000, Journal of gastroenterology and hepatology.
[6] S. Seki,et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis , 1995, The Lancet.
[7] Willis C. Maddrey,et al. EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. , 1999, Journal of hepatology.
[8] Y. Liaw. Role of hepatitis C virus in dual and triple hepatitis virus infection , 1995, Hepatology.
[9] E. Schiff,et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection , 2002, American Journal of Gastroenterology.
[10] L. Rostaing,et al. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. , 1995, Transplantation.
[11] S. Polywka,et al. Accuracy of HCV‐RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection , 2006, Journal of medical virology.
[12] J. Sánchez-Tapias,et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. , 2002, Transplantation.
[13] H. Nomura,et al. Short‐term interferon‐alfa therapy for acute hepatitis C: A randomized controlled trial , 2004, Hepatology.
[14] M. Chevallier,et al. [Early treatment of acute hepatitis C with interferon alpha-2b or interferon alpha-2b plus ribavirin: study of sixteen patients]. , 2003, Gastroenterologie clinique et biologique.
[15] B. Portmann,et al. Long-term outcome of hepatitis C infection after liver transplantation. , 1996, The New England journal of medicine.
[16] J. Mir,et al. Natural history of clinically compensated hepatitis C virus–related graft cirrhosis after liver transplantation , 2000, Hepatology.
[17] D. Yeshurun,et al. Hepatitis C virus-related arthritis: characteristics and response to therapy with interferon alpha. , 2000, Clinical and experimental rheumatology.
[18] B. Portmann,et al. Liver transplantation for primary hepatocellular carcinoma: tumor size and number determine outcome. , 1993, Journal of hepatology.
[19] V. Yu,et al. Recurrent hepatitis C virus hepatitis in liver transplant recipients receiving tacrolimus: association with rejection and increased immunosuppression after transplantation. , 1996, Surgery.
[20] W. Kim,et al. Burden of liver disease in the United States: Summary of a workshop , 2002, Hepatology.
[21] M. Manns,et al. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection , 2004, Journal of medical virology.
[22] M. Kedda,et al. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. , 1997, Gastroenterology.
[23] K. Batts,et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[24] A. Chutaputti. Adverse effects and other safety aspects of the hepatitis C antivirals , 2000, Journal of gastroenterology and hepatology.
[25] ndrea,et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.
[26] S. Agarwal,et al. Hepatitis C virus related cryoglobulinemic glomerulonephritis. , 2002, Journal of Association of Physicians of India.
[27] K. Reddy,et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. , 1998, Transplantation.
[28] L. Rostaing,et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[29] R. W. Mccollum. The natural history of hepatitis. , 1969, Bulletin of the New York Academy of Medicine.
[30] J. Ware,et al. Health‐related quality of life in chronic hepatitis C: Impact of disease and treatment response , 1999, Hepatology.
[31] G. Cilla,et al. Maternal-infant transmission of hepatitis C virus infection. , 1992, The Pediatric infectious disease journal.
[32] M. Houghton,et al. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. , 1998, Gastroenterology.
[33] A. Moya,et al. Contribution of donor age to the recent decrease in patient survival among HCV‐infected liver transplant recipients , 2002, Hepatology.
[34] William M. Lee,et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. , 2004, Gastroenterology.
[35] J. Hoofnagle,et al. Hepatitis C and renal disease: an update. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[36] A. Levey,et al. THE IMPACT OF PRETRANSPLANTATION HEPATITIS C INFECTION ON THE OUTCOME OF RENAL TRANSPLANTATION , 1995, Transplantation.
[37] K. Reddy,et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. , 2004, Gastroenterology.
[38] J. Crespo,et al. Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. , 1994, The American journal of gastroenterology.
[39] M. Buti,et al. Role of hepatitis B, C, and D viruses in dual and triple infection: Influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference , 2001, Hepatology.
[40] Edward A Belongia,et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. , 2009, Annals of internal medicine.
[41] British Society of Gastroenterology , 1963 .
[42] G. Everson,et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy , 2005, Hepatology.
[43] A. Levey,et al. Hepatitis C virus infection in dialysis and renal transplantation. , 1997, Kidney international.
[44] Y. Jeng,et al. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients , 2003, Hepatology.
[45] M. Narkewicz,et al. Safety, Efficacy and Pharmacokinetics of Peginterferon &agr;2a (40 kd) in Children With Chronic Hepatitis C , 2006, Journal of pediatric gastroenterology and nutrition.
[46] D. Payawal,et al. Does dual infection by hepatitis B and C viruses play an important role in the pathogenesis of hepatocellular carcinoma in Japan? , 1997, Cancer.
[47] J. Crowe,et al. Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection. , 1999, European journal of gastroenterology & hepatology.
[48] O. Chazouilleres,et al. Determinants of outcome of compensated hepatitis C virus‐related cirrhosis , 1998, Hepatology.
[49] Z. Gaciong,et al. Long-term results of treatment of chronic hepatitis B, C and D with interferon-α in renal allograft recipients , 1998 .
[50] R. Beasley. A significant sex--but not elective cesarean section--effect on mother-to-child transmission of hepatitis C virus infection. , 2005, The Journal of infectious diseases.
[51] D. Trichopoulos,et al. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. , 1991, JAMA.
[52] R. Busuttil,et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. , 1997, The American journal of gastroenterology.
[53] P. Ferenci. Treatment of hepatic encephalopathy. , 2001, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.
[54] X. Forns,et al. Hepatitis C virus kinetics during and immediately after liver transplantation , 2002, Hepatology.
[55] T. Maisonobe,et al. Hepatitis C virus infection and mixed cryoglobulinaemia vasculitis: a review of neurological complications. , 2005, AIDS.
[56] Has Afef Achbt. [Indications for liver transplantation. Text of recommendations - short version]. , 2005, Gastroenterologie clinique et biologique.
[57] W. Chow. Hepatitis C: Retreatment and treatment of patients with renal failure , 2000, Journal of gastroenterology and hepatology.
[58] J. Pawlotsky,et al. Use of virologic assays in the diagnosis and management of hepatitis C virus infection. , 2005, Clinics in liver disease.
[59] H J Alter,et al. Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome , 2000, Seminars in liver disease.
[60] J. Gisbert,et al. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. , 2003, Journal of hepatology.
[61] P. Glue,et al. The clinical pharmacology of ribavirin. , 1999, Seminars in liver disease.
[62] P. Simmonds,et al. Heterogeneity of hepatitis C virus genotypes in hemophilia: relationship with chronic liver disease. , 1995, Blood.
[63] Aljack Ma,et al. Dual infection with hepatitis C and B viruses : Clinical and histological study in Saudi patients , 1997 .
[64] M. Alter,et al. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. , 2003, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[65] M. Alter,et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. , 2005, The Journal of infectious diseases.
[66] B. Bastani,et al. Kidney disease in patients with chronic hepatitis c , 2001, Current gastroenterology reports.
[67] R. Gish,et al. A model to predict severe HCV‐related disease following liver transplantation , 2003, Hepatology.
[68] F. Carrat,et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. , 2004, JAMA.
[69] M. Buti,et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. , 2006, Journal of hepatology.
[70] D. Valla,et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. , 1994, Gastroenterology.
[71] P. Pontisso,et al. A multicenter controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Hepatitis Study Group of the Association of Italian Hemophilia Centers. , 1997, Blood.
[72] A. Muñoz,et al. The declining risk of post-transfusion hepatitis C virus infection. , 1992, The New England journal of medicine.
[73] P. Marcellin,et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. , 2004, Journal of hepatology.
[74] R. Rodby,et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. , 1993, Journal of the American Society of Nephrology : JASN.
[75] N. Mateva,et al. Prevalence of antibodies against hepatitis C virus and hepatitis B coinfection in healthy population in Bulgaria. A seroepidemiological study. , 2004, Minerva gastroenterologica e dietologica.
[76] V. Thakur,et al. Alpha‐interferon therapy in chronic hepatitis due to active dual infection with hepatitis B and C viruses , 1999, Journal of gastroenterology and hepatology.
[77] U. Steinbrecher,et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[78] N. Barshes,et al. The natural history of hepatitis C virus in pediatric liver transplant recipients , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[79] W. Jiménez,et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. , 1993, Gastroenterology.
[80] J. Gisbert,et al. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection , 2005, Alimentary pharmacology & therapeutics.
[81] B. Nathwani,et al. Hepatitis C Virus Infection in Patients with B-Cell Non-Hodgkin Lymphoma , 1997, Annals of Internal Medicine.
[82] Y. Liaw,et al. Impact of acute hepatitis B virus superinfection on chronic hepatitis c virus infection , 2000, American Journal of Gastroenterology.
[83] Sarin Sk. What should we advise about adjunctive therapies, including herbal medicines, for hepatitis C? , 2000 .
[84] F. Chisari,et al. Determinants of Viral Clearance and Persistence during Acute Hepatitis C Virus Infection , 2001, The Journal of experimental medicine.
[85] Y. Maor,et al. Non‐invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy? , 2006, Haemophilia.
[86] J. Devlin,et al. Indications for referral and assessment in adultliver transplantation: a clinical guideline , 1999, Gut.
[87] E. Tanaka,et al. Prevalence of antibody to hepatitis C virus in Japanese schoolchildren: comparison with adult blood donors. , 1992, The American journal of tropical medicine and hygiene.
[88] M. García-Carrasco,et al. Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection. , 2003, Rheumatology.
[89] E. Nicastri,et al. Contamination by hepatitis B and C viruses in the dialysis setting. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[90] W. Irving,et al. A comprehensive study of the association between hepatitis C virus and glomerulopathy. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[91] Establishment of the First International Standard for Nucleic Acid Amplification Technology (NAT) Assays for HCV RNA , 1999, Vox sanguinis.
[92] P. Francioli,et al. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[93] M. Quintana,et al. High-Dose and Long-Term Therapy of α Interferon in Hemophiliac Patients With Chronic C Virus Hepatitis , 1998 .
[94] J. Piette,et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[95] N. Terrault,et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus–infected patients awaiting liver transplantation , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[96] J. Montaner,et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. , 2004, The New England journal of medicine.
[97] T. Honda,et al. Anti‐HCV agent, ribavirin, elevates the activity of clotting factor VII in patients with hemophilia: a possible mechanism of decreased events of bleeding in patients with hemophilia by ribavirin , 2006, Journal of thrombosis and haemostasis : JTH.
[98] M. Deschaseaux,et al. Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing? , 2005, Transfusion.
[99] Z. Goodman,et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. , 2001, Journal of hepatology.
[100] B. Bacon,et al. Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[102] G. Borelli,et al. Hepatitis C Virus Infection in Patients with Essential Mixed Cryoglobulinemia , 1992, Annals of Internal Medicine.
[103] M. Ghany,et al. Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.
[104] B. Zimmerman,et al. Hepatitis C, cryoglobulinemia, and cirrhosis: A meta‐analysis , 2002, Hepatology.
[105] N. Key,et al. Hepatitis C in adults and adolescents with hemophilia: A randomized, controlled trial of interferon alfa‐2b and ribavirin , 2002, Hepatology.
[106] M. Newell,et al. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[107] J. Pawlotsky,et al. SERIAL QUANTITATIVE DETERMINATION OF HEPATITIS C VIRUS RNA LEVELS AFTER LIVER TRANSPLANTATION A USEFUL TEST FOR DIAGNOSIS OF HEPATITIS C VIRUS REINFECTION , 1995, Transplantation.
[108] H. Bismuth,et al. Liver Resection Versus Transplantation for Hepatocellular Carcinoma in Cirrhotic Patients , 1993, Annals of surgery.
[109] J. Kaldor,et al. Public health challenges in hepatitis C virus infection , 2000, Journal of gastroenterology and hepatology.
[110] Yasuyuki Arakawa,et al. Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan , 1999, Annals of Internal Medicine.
[111] C. Chu,et al. Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. , 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[112] M. Russo,et al. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety , 2003, American Journal of Gastroenterology.
[113] R. Purcell,et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. , 1991, The New England journal of medicine.
[114] G. Alexander,et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. , 1999, Gastroenterology.
[115] F. Fabrizi,et al. Meta‐analysis: interferon for the treatment of chronic hepatitis C in dialysis patients , 2003, Alimentary pharmacology & therapeutics.
[116] R. Fontana,et al. Noninvasive monitoring of patients with chronic hepatitis C , 2002, Hepatology.
[117] D. Dieterich,et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy , 2004, AIDS.
[118] R. Carithers. Liver transplantation , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[119] J. Campistol,et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[120] M. Sata,et al. Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy , 2000, Annals of Internal Medicine.
[121] W. Hardikar,et al. The silent infection: should we be testing for perinatal hepatitis C and, if so, how? , 2006, The Medical journal of Australia.
[122] L. Rostaing,et al. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. , 1996, Nephron.
[123] M. Schwartz,et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation , 1995, Hepatology.
[124] E. Tanaka,et al. Natural history of acute hepatitis C , 2000, Journal of gastroenterology and hepatology.
[125] A. Mocroft,et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. , 2005, The Journal of infectious diseases.
[126] F. Fabrizi,et al. Hepatitis C Virus Antibody Status and Survival After Renal Transplantation: Meta‐Analysis of Observational Studies , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[127] G. McCaughan,et al. Clinical assessment and incidence of hepatitis C RNA in 50 consecutive RIBA‐positive volunteer blood donors , 1992, The Medical journal of Australia.
[128] C. Graham,et al. Pegylated interferon α therapy in acute hepatitis C: Relation to hepatitis C virus–specific T cell response kinetics , 2004, Hepatology.
[129] P. Chossegros,et al. Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients. , 1997, Transplantation proceedings.
[130] N. Terrault,et al. Treating hepatitis C infection in liver transplant recipients , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[131] R. Wiesner,et al. Predictors of patient and graft survival following liver transplantation for hepatitis C , 1998, Hepatology.
[132] J. Devlin,et al. Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology. , 1999 .
[133] C. Chu,et al. Simultaneous acute infections with hepatitis non-A, non-B, and B viruses , 1982, Digestive Diseases and Sciences.
[134] H. Bonkovsky,et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in north america , 1998, Hepatology.
[135] M. Manns,et al. Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C , 2004, Hepatology.
[136] M. Delgado-Rodríguez,et al. Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users , 1999, European Journal of Epidemiology.
[137] G. Mazzucco,et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. , 2003, Kidney international.
[138] Y. Liaw. Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection , 2008, Journal of Gastroenterology.
[139] G. D'Amico,et al. Cryoglobulinemic glomerulonephritis: a membranoproliferative glomerulonephritis induced by hepatitis C virus. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[140] Christophe Combet,et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes , 2005, Hepatology.
[141] B. Portmann,et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. , 1996, Gastroenterology.
[142] A. Marrone,et al. Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection. , 2004, Journal of hepatology.
[143] Á. Figuera,et al. Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients , 2000, Bone Marrow Transplantation.
[144] Kenneth Koury,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[145] J. R. Contreras,et al. A significant sex--but not elective cesarean section--effect on mother-to-child transmission of hepatitis C virus infection , 2005 .
[146] P. Bioulac-Sage,et al. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus–reinfected liver , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[147] C. Chu,et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. , 2004, Gastroenterology.
[148] G. Fattovich,et al. Hepatitis C virus infection in chronic hepatitis B virus carriers. , 1991, The Journal of infectious diseases.
[149] J. Brown. Interferon therapy reduces the risk for hepatocellular carcinoma , 2000, Gut.
[150] S. Akhtar,et al. Hepatitis B and C: prevalence and risk factors associated with seropositivity among children in Karachi, Pakistan , 2006, BMC infectious diseases.
[151] K. Ishak,et al. Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo‐controlled double‐blind trial , 1998, Hepatology.
[152] V. Arroyo,et al. Compensated cirrhosis: Natural history and prognostic factors , 1987, Hepatology.
[153] Y. Oshiro,et al. Prevalence of hepatitis C virus infection in cases of B‐cell lymphoma in Japan , 2006, Histopathology.
[154] A. Heath,et al. Establishment of the First International Standard for Nucleic Acid Amplification Technology (NAT) Assays for HCV RNA , 1999, Vox Sanguinis.
[155] A. Inati,et al. Efficacy and tolerability of peginterferon alpha‐2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection , 2005, British journal of haematology.
[156] Shou-Dong Lee,et al. Multiple viral infection as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B: Application and limitations of the polymerase chain reaction , 1994, Hepatology.
[157] M. Andreu,et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. , 1993, Gastroenterology.
[158] M. Quintana,et al. High-dose and long-term therapy of alpha interferon in hemophiliac patients with chronic C virus hepatitis. , 1998, Blood.
[159] K. Matsuo,et al. Effect of hepatitis C virus infection on the risk of non‐Hodgkin's lymphoma: A meta‐analysis of epidemiological studies , 2004, Cancer science.
[160] NIH Consensus Statement on Management of Hepatitis C: 2002. , 2002, NIH consensus and state-of-the-science statements.
[161] K. Ruxrungtham,et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001 , 2003, AIDS.
[162] C. Chan,et al. Superinfection with hepatitis C virus in patients with symptomatic chronic hepatitis B. , 1991, Scandinavian journal of infectious diseases.
[163] G. Di Iorio,et al. Viral RNA in nerve tissues of patients with hepatitis C infection and peripheral neuropathy , 2003, Muscle & nerve.
[164] X. Forns,et al. HCV virological assessment. , 2006, Journal of hepatology.
[165] Sheng-Nan Lu,et al. Combination therapy with interferon‐α and ribavirin in patients with dual hepatitis B and hepatitis C virus infection , 2005, Journal of gastroenterology and hepatology.
[166] D. Pillay,et al. HIV and hepatitis C coinfection within the CAESAR study , 2004, HIV medicine.
[167] B. Rehermann,et al. Acute Hepatitis C: A Multifaceted Disease , 2005, Seminars in liver disease.
[168] D. Amarapurkar. Natural history of hepatitis C virus infection , 2000, Journal of gastroenterology and hepatology.
[169] M. Ansar,et al. Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in north Iran‐Rasht , 2002, Journal of viral hepatitis.
[170] S. Vento,et al. Infections and thalassaemia. , 2006, The Lancet. Infectious diseases.
[171] N. Hayashi,et al. Hepatitis C virus antibody and hepatitis C virus replication in chronic hepatitis B patients. , 1994, Journal of hepatology.
[172] R. Bennett,et al. Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients. , 1999, The American journal of gastroenterology.
[173] A. Jenke,et al. Peginterferon alfa‐2b plus ribavirin treatment in children and adolescents with chronic hepatitis C , 2005, Hepatology.
[174] W. Kim,et al. The burden of hepatitis C in the United States , 2002, Hepatology.
[175] S. Malnick,et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. , 2006, Gastroenterology.
[176] G. Fattovich,et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study , 1994 .
[177] P. Sogni,et al. Interest of transjugular liver biopsy in adult patients with haemophilia or other congenital bleeding disorders infected with hepatitis C virus , 2004, British journal of haematology.
[178] H. T. Head,et al. Global surveillance and control of hepatitis C , 1999 .
[179] J. Piette,et al. Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. , 2002, Journal of hepatology.
[180] R. Fisher,et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[181] E. Sokal,et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[182] T. Santantonio,et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. , 2005, Journal of hepatology.
[183] R. Wiesner,et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. , 1998, Transplantation.
[184] R. Purcell,et al. Hepatitis C virus-associated fulminant hepatic failure. , 1996, The New England journal of medicine.
[185] R. Wiesner,et al. Management of ascites in patients with cirrhosis. What to do when diuretics fail. , 1992, Postgraduate medicine.
[186] L. Seeff,et al. The natural history of chronic hepatitis C infection. , 1996, European journal of gastroenterology & hepatology.
[187] M. Weltman,et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. , 1995, Journal of viral hepatitis.
[188] J. Goedert,et al. Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.
[189] R. Wiesner,et al. Acute hepatic allograft rejection: Incidence, risk factors, and impact on outcome , 1998, Hepatology.
[190] T. Berg,et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: Evidence for rapid turnover of serum virions , 1996, Hepatology.
[191] R. Fanin,et al. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. , 1996, Blood.
[192] B. Pereira,et al. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[193] G. Colucci,et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. , 2003, Journal of hepatology.
[194] J. Emond,et al. Predictors of the cost of liver transplantation. , 1998, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[195] L. Seeff,et al. Natural history of chronic hepatitis C , 2002, Hepatology.
[196] A. Floreani,et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis , 1999, Cancer.
[197] Y. Shiratori,et al. Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course? , 2000, Journal of gastroenterology and hepatology.
[198] S. Fucharoen,et al. Prevalence and Clinical Significance of Hepatitis C Virus Infection in Thai Patients with Thalassemia , 2003, International journal of hematology.
[199] F. Fabrizi,et al. Treatment of chronic hepatitis C infection in patients with renal failure. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[200] L. Seeff,et al. Aasld Practice Guideline Diagnosis, Management, and Treatment of Hepatitis C , 2003 .
[201] R. Chung,et al. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. , 1998, Transplantation.
[202] M. Manns,et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. , 2002, Gastroenterology.
[203] A. Bruchfeld,et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[204] D. S. Bowden,et al. Chronic hepatitis C virus infection: genotyping and its clinical role. , 2006, Future microbiology.
[205] J. Hoofnagle,et al. National Institutes of Health Consensus Development Conference: Management of Hepatitis C: 2002 , 2002, Hepatology.
[206] D. Cortese,et al. Hepatopulmonary Syndrome: Current Concepts in Diagnostic and Therapeutic Considerations , 1994 .
[207] A. Mocroft,et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? , 2005, AIDS.
[208] S. Martin. [Hepatitis C in children]. , 2009, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.
[209] C. Trautwein,et al. Treatment of acute hepatitis C with interferon alfa-2b. , 2001, The New England journal of medicine.
[210] J. Goedert,et al. Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. , 2005, Blood.
[211] W. Vogel,et al. Prognosis and life expectancy in chronic liver disease , 1995, Digestive Diseases and Sciences.
[212] M. Weltman,et al. Coinfection with hepatitis B and C or B, C and δ viruses results in severe chronic liver disease and responds poorly to terferon‐a treatment , 1995 .
[213] T. Liang,et al. Hepatitis C — identifying patients with progressive liver injury , 2006, Hepatology.
[214] S. Banks,et al. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B , 1991, Hepatology.
[215] Ding‐Shinn Chen,et al. Transmission of hepatitis C virus in Asia: past and present perspectives , 2000, Journal of gastroenterology and hepatology.
[216] F. Farina,et al. Longitudinal Long-term Follow-up Study of Children with Vertically Acquired Hepatitis C Virus Infection , 2006, The Journal of international medical research.
[217] G. Dore,et al. Long‐term outcome of vertically acquired and post‐transfusion hepatitis C infection in children , 2004, Journal of gastroenterology and hepatology.
[218] G. Martorana,et al. The long‐term course of chronic hepatitis B , 1999, Hepatology.
[219] M. Shiffman,et al. Use of diagnostic testing for managing hepatitis C virus infection. , 2004, Seminars in liver disease.
[220] A. Alberti. Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. , 2005, Journal of hepatology.
[221] Z. Goodman,et al. Is an “à la carte” combination interferon alfa‐2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? , 2000, Hepatology.
[222] K. Bjøro,et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study , 2004, Hepatology.
[223] B Modell,et al. Global Epidemiology of Hemoglobin Disorders , 1998, Annals of the New York Academy of Sciences.
[224] G. Davis,et al. Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitis C virus infection. , 1994, Gastroenterology.
[225] J. Córdoba,et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. , 1998, Journal of hepatology.
[226] Claudio Michelassi,et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. , 2004, Seminars in arthritis and rheumatism.
[227] A. Abdulla,et al. Interferon-α in chronic hepatitis C infection in dialysis patients , 1999 .
[228] I. Bilbao,et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. , 2005, Journal of hepatology.
[229] A. Abdulla,et al. Interferon-alpha in chronic hepatitis C infection in dialysis patients. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[230] F. Rosendaal,et al. Mortality and causes of death in patients with hemophilia, 1992–2001: a prospective cohort study 1 , 2006, Journal of thrombosis and haemostasis : JTH.
[231] P. Cacoub,et al. Fatigue in patients with chronic hepatitis C , 2002, Journal of viral hepatitis.
[232] G. Zuin,et al. Clinical features and progression of perinatally acquired hepatitis C virus infection , 2003, Journal of medical virology.
[233] C. Alpers,et al. Renal manifestations of hepatitis C virus infection. , 1994, Kidney international.
[234] Y. Shiratori,et al. Long‐term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C , 2000, Journal of gastroenterology and hepatology.
[235] Shiuan-Chih Chen,et al. Seroepidemiology of hepatitis A, B, C, and E viruses infection among preschool children in Taiwan , 2006, Journal of medical virology.
[236] N. Gruener,et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. , 2003, Gastroenterology.
[237] H. Margolis,et al. The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States , 2000, Hepatology.
[238] Seth D. Crockett,et al. Annals of Clinical Microbiology and Anti microbials , 2005 .
[239] Stephen L. Chen,et al. The Natural History of Hepatitis C Virus (HCV) Infection , 2006, International journal of medical sciences.
[240] D. Cooper,et al. The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses , 2001, Current opinion in infectious diseases.
[241] J. Lake,et al. Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation. , 1996, Transplantation.
[242] J. Jeekel,et al. RECOMBINANT LEUCOCYTE INTERFERON A INDUCES STEROID-RESISTANT ACUTE VASCULAR REJECTION EPISODES IN RENAL TRANSPLANT RECIPIENTS , 1984, The Lancet.
[243] V. Paradis,et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection , 1995, Hepatology.
[244] J. Ludwig,et al. The long‐term pathological evolution of chronic hepatitis C , 1996, Hepatology.
[245] A. Nicolucci,et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. , 2002, Blood.
[246] M. Fried,et al. Optimizing treatment regimens in hepatitis C. , 2006, Clinics in liver disease.
[247] H. Van Vlierberghe,et al. Treatment of acute hepatitis C with interferon α‐2b: early initiation of treatment is the most effective predictive factor of sustained viral response , 2004, Alimentary pharmacology & therapeutics.
[248] A. Alberti,et al. Management of hepatitis C. , 2003, Journal of hepatology.
[249] N. Chalasani,et al. Peginterferon alfa‐2a for hepatitis C after liver transplantation: Two randomized, controlled trials , 2005, Hepatology.
[250] J. Kaldor,et al. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies , 2006, Journal of viral hepatitis.
[251] N. Terrault,et al. Applicability, Tolerability and Efficacy of Preemptive Antiviral Therapy in Hepatitis C‐Infected Patients Undergoing Liver Transplantation , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[252] L. Ferrell,et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. , 2000, Journal of hepatology.
[253] P. Giangrande,et al. Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.
[254] S. Sato,et al. Coinfection of hepatitis C virus in patients with chronic hepatitis B infection. , 1994, Journal of hepatology.
[255] C. Chu,et al. The role of hepatitis C virus in fulminant viral hepatitis in an area with endemic hepatitis A and B. , 1994, Gastroenterology.
[256] S. Ryder. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults , 2003, Gut.
[257] J. Berlin,et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. , 2002, Gastroenterology.
[258] David H. Lee,et al. Morbidity of Chronic Hepatitis C as Seen in a Tertiary Care Medical Center , 2004, Digestive Diseases and Sciences.
[259] Ming‐Lung Yu,et al. Viral Interaction and Responses in Chronic Hepatitis C and B Coinfected Patients with Interferon-Alpha plus Ribavirin Combination Therapy , 2005, Antiviral therapy.
[260] Y. Liaw. Concurrent hepatitis B and C virus infection: Is hepatitis C virus stronger? , 2001, Journal of gastroenterology and hepatology.
[261] N. Afdhal,et al. Duration of peginterferon therapy in acute hepatitis C: A randomized trial , 2006, Hepatology.
[262] H. El‐Serag,et al. Risk factors for the rising rates of primary liver cancer in the United States. , 2000, Archives of internal medicine.
[263] G. Klintmalm,et al. 12‐month follow‐up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[264] M. Vivarelli,et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[265] D. Gretch,et al. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. , 1995, Journal of the American Society of Nephrology : JASN.
[266] Dieter Häussinger,et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.
[267] A. Andriulli,et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. , 2005, The New England journal of medicine.
[268] J. Piette,et al. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. , 2005, Arthritis and rheumatism.
[269] P. Ruiz,et al. Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients. , 2005, Transplantation proceedings.
[270] N. Afdhal. The natural history of hepatitis C. , 2004, Seminars in liver disease.
[271] O. Selberg,et al. Identification of high‐ and low‐risk patients before liver transplantation: A prospective cohort study of nutritional and metabolic parameters in 150 patients , 1997, Hepatology.
[272] F. Delmonico,et al. Liver transplantation for primary hepatic cancer. , 1992, Transplantation.